The Impact of Immune-Related Adverse Events on the Survival of Patients Treated with Immune Checkpoint Inhibitors: The Distinct Role of Cardiac Toxicities.

J Clin Med · 2025 · PMC12609892 · PMID 41227189

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Conversely, patients with cardiac toxicities did not derive the same advantage, with similar OS and PFS values that did not reach statistical significance: median OS 15.0 months (95% CI, 13.3–19.3) vs. 15.8 months (95% CI, 12.0–30.3), 1.11 (95% CI, 0.78–1.57) HR; median PFS 9.1 months (95% CI, 7.6–10.4) vs. 8.1 months (95% CI, 5.3–19.3), 1.003 (95% CI, 0.72–1.39) HR.

also in 111,027 other papers

a clear trendno p-value reported

In head and neck cancer, patients with non-cardiac irAEs in our study showed a clear trend toward improved OS and PFS, although statistical significance was not reached.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.